Skip to content
Open access

ROLE OF AMPHOTERICIN B NASAL IRRIGATION IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS: A QUASI-EXPERIMENTAL STUDY AT LRH PESHAWAR

Sep 2026 · Khyber Journal of Medical Sciences · Vol 19 · 0 citations · 23 references

TL;DR

Post-treatment symptom scores were lower than baseline scores; however, the uncontrolled design, study-specific non-validated outcome measure, and incompletely specified treatment protocol preclude conclusions regarding efficacy or routine clinical use.

Abstract

Objective: To assess the change in clinical symptom scores and describe adverse effects following amphotericin B nasal irrigation in adults with chronic rhinosinusitis with nasal polyps. Methods: This single-group pretest-posttest quasi-experimental study was conducted in the Department of Otorhinolaryngology, Lady Reading Hospital, Peshawar, from 24 July 2025 to 24 January 2026. Eighty-nine consecutively recruited adults with complete paired records were assessed using a study-specific four-item symptom score. Normality was evaluated with the Shapiro-Wilk test. Because paired score differences were non-normally distributed, pre-treatment and post-treatment scores were compared using two-sided Wilcoxon signed-rank tests. Results: The median age was 41 years (interquartile range [IQR], 36-46), and 46 (51.69%) participants were men. The median total symptom score decreased from 10 (IQR, 9-10) before treatment to 5 (IQR, 5-6) after treatment, with a median paired reduction of 5 points (IQR, 4-5; p<0.001). All four symptom components also showed lower post-treatment scores (all p<0.001). Minor local adverse effects were recorded in 51 (57.30%) participants: mild irritation in 24 (26.97%), mild dryness in 14 (15.73%), and burning sensation in 13 (14.61%). No serious adverse effect was recorded. Conclusions: Post-treatment symptom scores were lower than baseline scores; however, the uncontrolled design, study-specific non-validated outcome measure, and incompletely specified treatment protocol preclude conclusions regarding efficacy or routine clinical use.

Read PDF

Similar papers

Open access Oct 2026

Therapeutic Value of Budesonide Nasal Irrigation for Postoperative Maintenance of Chronic Rhinosinusitis: A Real-World Study

Objectives: Budesonide irrigation (BI) has emerged as an effective postoperative topical therapy for chronic rhinosinusitis (CRS), providing improved drug delivery compared with conventional intranasal corticosteroid sprays. However, evidence regarding its role as a maintenance strategy during the critical postoperativ...

S. T. Kim, Jin-Young Min · 0 citations
Open access Oct 2026

Efficacy and safety of tezepelumab in Japanese patients with chronic rhinosinusitis with nasal polyps: A subpopulation analysis of the randomized WAYPOINT study.

OBJECTIVE Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, effectively reduced polyp size in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Tezepelumab also reduced the need for nasal polyp surgery and systemic corticosteroids (SCS) in the phase 3 WAYPOINT study across 10 countri...

N. Otori, Daiju Sakurai, Genki Iwai et al. · 0 citations
Open access Sep 2026

Clinical Effects of Adjunctive Shoseiryuto Therapy in Refractory Eosinophilic Chronic Rhinosinusitis: A Pilot Retrospective Case Series Focusing on Mucus‐Related Symptoms

To evaluate the efficacy and safety of adjunctive shoseiryuto, a traditional Japanese Kampo medicine, in patients with refractory eosinophilic chronic rhinosinusitis (ECRS), with particular attention to mucus‐related symptoms. This retrospective pilot case series was conducted at Osaka Medical and Pharmace...

Yusuke Kikuoka · 0 citations
Open access Sep 2026

Effects of dupilumab on nasal mucociliary clearance in severe CRSwNP: evaluation of the saccharin test as an objective outcome measure.

Preliminary findings support the potential role of the saccharin test as a simple, objective tool for monitoring response to biologic therapy and support the potential role of the saccharin test as a simple, objective tool for monitoring response to biologic therapy.

G. Pagliuca, Veronica Clemenzi, S. Martellucci et al. · 0 citations
Oct 2026

Efficacy of Dupilumab for Patients with Chronic Rhinosinusitis without Nasal Polyps: a Randomized Double-Blind Placebo Controlled Phase II Study.

The observed trend toward enhanced benefit in T2-high patients supports the potential for endotype-directed therapy and underscores the need for larger studies to evaluate the role of T2-targeted biologics in CRSsNP management.

J. Tversky, Andrew P. Lane, John T. Schroeder et al. · 0 citations
Open access Oct 2026

Sinonasal Histopathological Changes After 12 Months of Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps

Background/Objectives: Dupilumab blocks the interleukin-4 receptor alpha (IL-4Rα) subunit, thereby inhibiting IL-4- and IL-13-mediated signaling, and is an effective treatment for severe chronic rhinosinusitis with nasal polyps (CRSwNP). This study assessed clinical response and histopathological changes reflecting eos...

B. Kamiński, Dominika Ochab, Janusz Kopczyński et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.